X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
The dark horse makes its move - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Nov 26, 1999

    The dark horse makes its move

    Name the company that was the first to launch non-CFC metered dose salbutamol inhaler (anti-asthmatic) outside the US and Europe. One hint - it is an Indian company. If you guessed Ranbaxy or Dr Reddy's, the leaders in domestic research and development, you missed the target. The company that launched these products is Cipla Limited.

    Cipla is India's second largest company (4.2 percent market share) having over 200 brands in its product portfolio, a number which are leaders in their respective segments. Its efforts are focused in the areas of asthma, antibiotics, cardiovascular and anti-inflammatory and its new focus areas are anti-viral and anti-cancer. The company is often termed as a super store of asthma products in view of its vast range in this segment. Cipla shot into limelight when, fed up with the demands of its medical representative team, it decided to terminate their employment. As an alternative, the company opted for direct marketing to doctors, a method that proved to be very successful.

    Cipla is one of the leaders in domestic pharmaceutical research and development (R&D). The company introduced 33 new molecules between financial year 1996 and financial year 1998 and continues to introduce products at a blistering pace in order to keep ahead of competition.

    In view of the introduction of product patents by 2005, the company has initiated research on new molecules as against reverse engineering of existing molecules. It has already filed two international patents for improved delivery systems for two molecules, even as it is working on novel delivery systems for other molecules. The company, however, has as yet to make a break through in terms of licensing deals like the ones entered into by Ranbaxy with Bayer AG and Dr Reddy's with Novo Nordisk.

    Cipla has historically focused on the domestic markets to generate growth. However, over the past few years, it has dramatically increased its presence in the international markets, with exports accounting for 19 percent of sales in FY99. The company is now targeting to generate 35 percent of its sales in the international markets (with focus on USA) within five years. Cipla is well placed to achieve this target.

    The company has four plants of which three have US Food and Drug Administration (FDA) approval. This permits the company to export to various international markets without being subject to constant quality controls. As part of the same strategy, the company has decided to focus on the export of complex generics. This is expected to limit competition while at the same time permit the company to earn higher margins. It has already filed 8 abbreviated new drug applications for such products. As the company has decided to focus on the US markets, it is actively considering setting up facilities in India to exclusively cater to the US markets.

    (Rs m) 2QFY2000 2QFY1999 Change
    Net Sales 1,997 1,615 23.7%
    Other Income 71 74 -4.1%
    Expenditure 1,549 1,128 37.3%
    Interest 4 12 -67.5%
    Depreciation 38 28 33.9%
    Profit before Tax 478 421 13.5%
    Tax 120 110 9.1%
    Profit after Tax 358 311 15.0%
    Net profit margin 17.9% 19.3%  

    Cipla's profitability, however, continues to depend on the whims of the National Pharmaceutical Pricing Authority (NPPA), which has the authority to set the prices of various drugs that fall within its ambit. 55 percent of Cipla's sales fall within the purview of the NPPA, making it susceptible to volatility in earnings as drug prices are revised. Although the committee formed for reviewing the drug price control order has put forward recommendations that will dilute the powers of the Authority considerably, it is unsure whether these will be accepted.

    Another concern pertains to the company's dependence on imports to meet its raw material requirements (30 percent of its raw material requirements are imported). Although the company has a natural hedge in the form of exports, a sustained depreciation in the value of the Indian Rupee could exert a downward pressure on margins.

    The competition in the domestic markets is expected to become more fierce in the coming years, as MNCs, which already have a presence in India, start to launch their patented products in the domestic market. This could, once again, adversely affect the profitability of the company.

    Cipla is trying to leverage its cost competitiveness and well developed research facilities into converting itself into a global generics company. It also continues to press ahead with its plans to develop new molecules and better delivery systems for existing molecules.

     

     

    Equitymaster requests your view! Post a comment on "The dark horse makes its move". Click here!

      
     

    More Views on News

    Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

    Mar 8, 2017

    Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

    Sep 19, 2016

    Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    CIPLA SHARE PRICE


    Aug 18, 2017 (Close)

    TRACK CIPLA

    CIPLA 8-QTR ANALYSIS

    Detailed Quarterly Results With Charts

    COMPARE CIPLA WITH

    MARKET STATS